Please assess the completion status of the following clinical trial:

Trial Title: Low-dose KETamine as an Adjunct to MOrphine for Acute Pain in the ED

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Emergency Department admission~2. Age ≥ 18 years~3. NRS ≥ 5~4. Stable vital signs defined as systolic blood pressure ≥ 90 mmHg, heart rate between 60 and 150 per minute, respiratory rate between 8 and 26 per minute, oxygen saturation greater than or equal to 92%~Exclusion Criteria:~1. Initial management by trauma-team~2. Systolic blood pressure ≥ 180mmHg, severe untreated arrhythmia, unstable angina, recent myocardial infarction (\< 30 days), severe heart-failure (Ejection fraction \< 40 %)~3. Symptoms of untreated hyperthyroidism~4. Cirrhosis with ascites~5. Known/suspected pregnancy or breastfeeding~6. Patients for whom consent is not obtainable or psychiatric forced treatment.~7. Previously enrolled in the trial~8. Psychiatric illness prior to admission defined as prior psychosis/schizophrenia~9. Untreated diagnosed glaucoma~10. Known hypersensitivity to ketamine or to any excipient or prior use of ketamine with a negative experience (i.e. hallucinations)~11. Patient clearly influenced by drugs or alcohol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention, low-dose ketamine (Type: EXPERIMENTAL): Two 1 ml syringes with Esketamine (5 mg/ml) will be prepared and study drug will be administered as intravenous bolus dose, 0,1 mg/kg. The study drug will be administered after an intravenous morphine dose.
- Placebo (Type: PLACEBO_COMPARATOR): Two 1 ml syringes with saline will be prepared and study drug will be administered as intravenous dose, same volume as if Esketamine. The placebo drug will be administered after an intravenous morphine dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).